Dr. Selig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Boston, MA 02115Phone+1 617-525-6841
Education & Training
University of Colorado School of Medicine Anschutz Medical CampusClass of 2007
Brigham and Women's HospitalResidency, Internal Medicine
Certifications & Licensure
MA State Medical License 2007 - 2012
Publications & Presentations
PubMed
- 70 citationsBiology of advanced uveal melanoma and next steps for clinical therapeuticsJason J. Luke, Pierre L. Triozzi, Kyle C. McKenna, Erwin G. Van Meir, Jeffrey E. Gershenwald
Pigment Cell & Melanoma Research. 2015-03-01 - 86 citationsAltered Chromosomal Positioning, Compaction, and Gene Expression with a Lamin A/C Gene MutationStephanie K. Mewborn, Megan J. Puckelwartz, Fida Abuisneineh, John Fahrenbach, Yuan Zhang
Plos One. 2010-12-14 - 80 citationsMissense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.Shay Tzur, Saharon Rosset, Revital Shemer, Guennady Yudkovsky, Sara Selig
Human Genetics. 2010-09-01
Press Mentions
Immunocore Announces FDA Approval of KIMMTRAK® (Tebentafusp-Tebn) for the Treatment of Unresectable or Metastatic Uveal MelanomaJanuary 27th, 2022- Melanoma Research Foundation Launches Historic Patient-Reported Ocular Melanoma RegistryMay 10th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
